LDS/Medical Tests/PAX2, Immunohistochemistry, Tissue

PAX2, Immunohistochemistry, Tissue

PAX2 (Paired Box Gene 2) is a member of the PAX gene family that encodes transcription factors critical for organogenesis, particularly of the kidney and Müllerian system. The PAX2 protein, located on chromosome 10q24.3, is essential in nephrogenesis and genital tract development. Mutations are associated with renal coloboma syndrome, a congenital disorder involving renal hypoplasia and optic nerve anomalies.

In immunohistochemistry, PAX2 demonstrates nuclear localization, consistent with its role as a transcription factor. In normal tissues, it is expressed in the nuclei of renal distal tubules, loops of Henle, and collecting ducts. Within renal neoplasms, expression varies by subtype, approximately 50–93% in clear cell RCC, 53–100% in papillary RCC, and 6–83% in chromophobe RCC. Although PAX2 shows slightly lower sensitivity than PAX8, it demonstrates higher specificity for renal and Müllerian epithelial tumors and is typically absent in urothelial, thyroid, and thymic epithelial neoplasms.

In gynecologic malignancies, PAX2 expression is observed in 27–67% of ovarian serous carcinomas and 40–50% of endometrioid and clear cell carcinomas. It helps distinguish primary ovarian carcinomas from metastatic breast carcinomas, as the latter lack PAX2 expression. Similarly, PAX2 aids in differentiating Müllerian serous carcinoma from peritoneal mesothelioma and nephrogenic adenoma from prostatic adenocarcinoma. Loss of PAX2 expression is a feature of endocervical adenocarcinoma.

Although early studies reported PAX2 immunoreactivity in B-cell lymphomas and rhabdomyosarcomas, this was likely due to cross-reactivity of older polyclonal antibodies with other PAX proteins (e.g., PAX5 in B-cells and PAX3/7 in skeletal muscle). The use of monoclonal antibodies has improved specificity, though large comparative validation studies remain limited.

Overall, PAX2 IHC is a valuable adjunct in confirming renal and Müllerian epithelial origin in tumors of uncertain primary site. However, because PAX8 demonstrates broader sensitivity and also marks thyroid and thymic neoplasms, it is often used in combination with or in preference to PAX2.

  • As an aid in the diagnosis of primary renal tumors
  • Confirms renal epithelial origin in primary and metastatic tumors
  • As an aid in the diagnosis of gynecological (Mullerian) tumors including ovarian and endometrial carcinomas
  • Helps distinguish nephrogenic adenoma (PAX2 positive) from prostatic adenocarcinoma (PAX2 negative)
  • Supports diagnosis of metastatic renal cell carcinoma in extra-renal sites
  • May aid in identifying small round cell tumors of uncertain origin
| **Result** | **Expected Findings** | **Interpretation** | | ------------ | ----------------------------------------------------------------------------------------------------- | -------------------------------------------------------- | | **Positive** | Distinct **nuclear staining** in tumor cells; may be focal or diffuse, weak to strong intensity. | Indicates renal or Müllerian epithelial differentiation. | | **Negative** | Absence of nuclear staining in tumor cells; cytoplasmic or membranous staining should be disregarded. | Suggests non-renal or non-Müllerian origin. |

Normal pattern varies between tissues and a definitive reference does not exist in general

Immunohistochemistry (IHC).

Formalin-fixed paraffin embedded (FFPE) tissue.

Stability

FFPE tissues are stable at room temperature for longer.

For renal tumors: BUN, eGFR, electrolytes, liver panel, CBC, erythropoietin, LDH, calcium, urinalysis, urine cytology. For gynecologic tumors: CA-125, HE4, CEA, CA 19-9, CA 15-3, β-hCG, AFP, LDH, ER/PR receptor testing, comprehensive metabolic panel.
1 to 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login